CKD-MBD Management: Are Global Guidelines Enough?
"Bridging the Gap Between International Standards and Local Realities in Chronic Kidney Disease-Mineral Bone Disorder Treatment"
The term 'chronic kidney disease-mineral bone disorder' (CKD-MBD) highlights a systemic syndrome impacting cardiovascular health and overall survival. In response, numerous countries have established clinical guidelines to enhance patient outcomes. The Kidney Disease Outcome Quality Initiative (KDOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines are globally recognized and used, but questions remain about their universal applicability.
The effectiveness of these global guidelines can be influenced by differences in healthcare systems and societal factors, which may limit their widespread application. Data from Korean registries and the Dialysis Outcomes and Practice Patterns Study (DOPPS) indicates that many dialysis patients do not consistently meet the KDOQI and KDIGO targets for serum calcium, phosphorus, and PTH levels. This discrepancy highlights a gap between global guidelines and local practices.
Addressing this gap necessitates studies comparing outcomes of Korean CKD-MBD patients under current practices against those suggested by global guidelines, and identifying region-specific mineral targets linked to improved outcomes.
Guideline-Based CKD-MBD Assessment
CKD is a prevalent, progressive condition involving gradual loss of kidney function, and its management requires a multidisciplinary approach. The KDOQI guidance states that no single diagnostic procedure or test can accurately evaluate the full spectrum of bone disorders in CKD. For the bone component of CKD-MBD in stages 3-5D, bone biopsy-based histological analysis is identified as the gold-standard diagnostic approach. Vascular calcification and arterial dysfunction related to CKD-MBD may also contribute to the higher cardiovascular morbidity and mortality seen in patients with CKD.
From CKD Definition to CKD-MBD
CKD was redefined in the new millennium as an alteration of kidney morphology, function, blood, or urine composition lasting at least three months. As kidney function declines, mineral homeostasis progressively deteriorates, disrupting serum and tissue concentrations of phosphorus and calcium and changing circulating hormone levels. CKD-MBD encompasses abnormalities in calcium, phosphate, parathyroid hormone, and vitamin D metabolism, along with bone disease and vascular or soft-tissue calcification. The 2017 KDIGO update noted that understanding of CKD-MBD pathophysiology had improved since the 2009 guideline, although high-quality clinical evidence for specific management decisions remained limited.
Why One-Size-Fits-All Doesn't Work: Tailoring CKD-MBD Treatment
While international guidelines provide a foundation for CKD-MBD management, healthcare providers must consider patient populations' unique characteristics and needs. In Korea, the Korean Society of Nephrology has tracked end-stage renal disease (ESRD) since 1986, but comprehensive mineral data collection began in 2012. According to 2013 data, Korea had nearly 60,000 dialysis patients, with average phosphorus levels around 4.94±1.63 mg/dL in hemodialysis patients and 5.05±1.56 mg/dL in peritoneal dialysis patients. Average calcium levels were 8.87±0.89 mg/dL and 8.74±0.91 mg/dL, respectively. Although these averages seem acceptable, the wide standard deviations suggest considerable variability.
- KDOQI (2003): Recommends maintaining serum phosphorus between 3.5 and 5.5 mg/dL in CKD stages 5 and 5D, slightly above normal levels.
- KDIGO (2009): Suggests lowering phosphorus levels toward the normal range in CKD stage 5D. Both guidelines have limited evidence.
Current KDIGO Guidance
The KDIGO CKD-MBD guideline remains a central reference for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. The KDIGO guidelines page identifies the KDIGO 2017 CKD-MBD Guideline as a current guideline resource. Its focus reflects the need to address mineral and bone disorders within the broader clinical management of chronic kidney disease. The guideline is therefore an important foundation for current reviews of CKD-MBD care.
Beyond a Single CKD-MBD Syndrome
KDIGO's CKD-MBD controversies report encourages management through two primary syndromes: CKD-associated osteoporosis and CKD-associated cardiovascular disease. The first emphasizes fracture prevention and bone health, while the second addresses vascular calcification and cardiac complications. Reported treatment strategies include calcimimetic agents, vitamin D and its analogues, bisphosphonates, denosumab, and calcitriol. The National Kidney Foundation notes that CKD-MBD risk is higher in later CKD stages and highest among people with kidney failure receiving dialysis, where changes can weaken bones and damage the heart and blood vessels.
Interrelated Treatment Options
CKD-MBD in kidney failure is characterized by interrelated features that include hyperparathyroidism, hyperphosphatemia, and hypocalcemia. The treatment options identified in the reviewed source include active vitamin D sterols, calcimimetics, and phosphate binders. These therapies may be used alone or in combination. This treatment landscape reflects the interconnected nature of the biochemical abnormalities involved in CKD-MBD.
Local Data, Global Impact: Optimizing CKD-MBD Care
Effectively managing CKD-MBD requires a nuanced approach, integrating global guidelines with regional data to achieve optimal health outcomes. As research continues and dialysis management evolves, healthcare strategies must be refined to reflect the unique needs of each population, ensuring that standardized practices translate into tangible benefits for patients.
Evidence After the 2017 Update
The 2017 KDIGO CKD-MBD guideline addressed the diagnosis, evaluation, prevention, and treatment of CKD-MBD. Since its publication, new evidence has emerged on evaluating disordered mineral metabolism and bone quality and turnover. Later work has also examined approaches to identifying and inhibiting relevant disease processes. CKD-MBD is highly prevalent in dialysis patients, and appropriate treatment is considered important for improving outcomes.
A Systemic Kidney Disease Complication
CKD-MBD is a systemic disorder of mineral metabolism that is specific to kidney disease. It involves dysregulation of phosphate, calcium, fibroblast growth factor 23, parathyroid hormone, and vitamin D. These disturbances can produce abnormalities in bone architecture, vascular calcification, and systemic mineral balance. The condition therefore extends beyond an isolated bone problem and requires attention to multiple interacting mineral and hormonal pathways.
Variation in Real-World Care
Management of CKD-MBD diverges among clinicians despite the existence of guidelines. The utility of serum bone turnover markers remains controversial during treatment of secondary hyperparathyroidism in dialysis patients because treatments can affect different bone surfaces in different ways. Case-finding approaches focused on high-risk groups, including people with diabetes, hypertension, and cardiovascular disease, may be more cost-effective for early CKD detection. Timely referral and escalation from primary care to specialists can help prevent unnecessary progression to advanced disease.